The abstract is read at the publisher; the summary is JClub's.
xCas12m is a hypercompact CRISPR-Cas12m variant that enables potent, specific epigenome editing in human cells and supports single-AAV delivery.
- Why it matters: Large dCas proteins hinder AAV delivery for programmable epigenome modulation, limiting therapeutic feasibility.
- What they did: The team identified miniature subtype V-M CRISPR-Cas12m from Pelomicrobium methylotrophicum, solved its target-binding mechanism by cryo-EM, then used deep mutational scanning and protein engineering to create xCas12m and xCas12m-CRISPRoff in a single AAV vector.
- The result: In a mouse model, xCas12m-CRISPRoff produced durable epigenetic silencing and effective inhibition of hepatitis B virus infection, supporting clinical translation of compact epigenetic therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.